Skip to Main Content

Author Details

Stacey J Adam
Foundation for the National Institutes of Health
2004
29
16
PMIDPaper TitleJournal TitlePublished Year
36633838Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.JAMA2023
37677122Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).JCO Precis Oncol2023
37435958Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank.Clin Infect Dis2023
37069219The importance of appropriate selection of clinical endpoints in outpatient COVID-19 clinical trials.Commun Med (Lond)2023
36730407The NIH-led research response to COVID-19.Science2023
36269852Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.JAMA2022
36207533MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes.Oncogene2022
33419780Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC).Clin Cancer Res2021
34495876Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines-Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical Trials.Crit Care Med2021
34181444Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics.Ann Intern Med2021
34321279Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.Clin Cancer Res2021
32988968Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation.Clin Cancer Res2020
33125909Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.Lancet Oncol2020
32805488MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC.Mol Ther Nucleic Acids2020
30273184The Partnership for Accelerating Cancer Therapies.Cancer J2018
30652552Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.JCO Clin Cancer Inform2018
25784651p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia.Oncotarget2015
25964345MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism.Proc Natl Acad Sci U S A2015
23178486STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma.Oncogene2013
22654667Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis.PLoS Genet2012
21969595Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.Proc Natl Acad Sci U S A2011
18374155A method to generate genetically defined tumors in pigs.Methods Enzymol2008
18773055Development of a swine model of secondary liver tumor from a genetically induced swine fibroblast cell line.HPB (Oxford)2008
19047133Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma.Cancer Res2008
16964292Genetic induction of tumorigenesis in swine.Oncogene2007
16687931Genetically engineered human cancer models utilizing mammalian transgene expression.Cell Cycle2006
17174914Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.Curr Biol2006
16267004A network of genetic events sufficient to convert normal human cells to a tumorigenic state.Cancer Res2005
15464859Alpha7 nicotinic acetylcholine receptors targeted by cholinergic developmental neurotoxicants: nicotine and chlorpyrifos.Brain Res Bull2004
  • 1 - 29 of 29

Recommended Authors

Mark A Murakami
Dana-Farber Cancer Institute
Career Start Year 2015
Number of shared co-authors 1
Victor Olivas
University of California san francisco
Career Start Year 2012
Number of shared co-authors 2
Kien Pham
Yale School of Public Health
Career Start Year 2012
Number of shared co-authors 0
Minhyung Kim
Roswell Park Comprehensive Cancer Center
Career Start Year 2010
Number of shared co-authors 0
John T Poirier
Laura and Isaac Perlmutter Cancer Center
Career Start Year 2007
Number of shared co-authors 2
Elizabeth Stewart
St Jude Children's Research Hospital
Career Start Year 2006
Number of shared co-authors 1
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 1
Donghui Cheng
University of California los angeles
Career Start Year 2003
Number of shared co-authors 0
Kristopher K Frese
Cancer Research UK Manchester Institute, University of Manchester
Career Start Year 2003
Number of shared co-authors 2
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 2
Chi-Ping Day
Center for Cancer Research, National Cancer Institute
Career Start Year 2002
Number of shared co-authors 2
Monte M Winslow
Stanford University School of Medicine
Career Start Year 2002
Number of shared co-authors 3
Ping Guo
Steadman Philippon Research Institute, Center for Regenerative Sports Medicine
Career Start Year 2001
Number of shared co-authors 0
Eric A Collisson
University of California san francisco
Career Start Year 1999
Number of shared co-authors 2
Annette T Byrne
Royal College of Surgeons in Ireland (RCSI)
Career Start Year 1999
Number of shared co-authors 1
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 1
Lianbo Yu
The Ohio State University
Career Start Year 1997
Number of shared co-authors 0
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 0
Christopher Ryan Miller
University of Illinois at Urbana-Champaign
Career Start Year 1996
Number of shared co-authors 1
Alexander D Borowsky
University of California Davis Health
Career Start Year 1995
Number of shared co-authors 1
Jorge Nieva
Norris Comprehensive Cancer Center, University of Southern California
Career Start Year 1995
Number of shared co-authors 2
Andrei Goga
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 1
Neal C Goodwin
Career Start Year 1992
Number of shared co-authors 1
Nabeel Bardeesy
Massachusetts General Hospital
Career Start Year 1992
Number of shared co-authors 3
David A Largaespada
University of Minnesota
Career Start Year 1990
Number of shared co-authors 2
Chand Khanna
National Cancer Institute, National Institutes of Health
Career Start Year 1989
Number of shared co-authors 3
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 7
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 5
David J Adams
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 0
Norman E Sharpless
National Cancer Institute
Career Start Year 1945
Number of shared co-authors 2

Collaborators

Christopher J Lindsell
Duke University
Co-authored papers 3
Mark S Sulkowski
Johns Hopkins University School of Medicine
Co-authored papers 3
Susanna Naggie
Duke Clinical Research Institute and Duke University School of Medicine
Co-authored papers 3
Adrian F Hernandez
Duke University Medical Center
Co-authored papers 3
David R Boulware
University of Minnesota
Co-authored papers 3
Kathleen M McTigue
University of Pittsburgh
Co-authored papers 2
Mithat Gonen
Co-authored papers 2
Gary Michael Felker
Duke University School of Medicine
Co-authored papers 2
Chaya S Moskowitz
Memorial Sloan Kettering Cancer Center.
Co-authored papers 2
Ruxandra Draghia-Akli
The Janssen Pharmaceutical Companies of Johnson & Johnson
Co-authored papers 2
James H Doroshow
National Cancer Institute, National Institutes of Health
Co-authored papers 2
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 2
Elizabeth A Shenkman
University of Florida
Co-authored papers 2
Allison DeLong
Duke Clinical Research Institute, Duke University
Co-authored papers 2
Nina T Gentile
Lewis Katz School of Medicine at Temple University
Co-authored papers 2
Peter W Marks
Center for Biologics Evaluation and Research
Co-authored papers 2
Judith S Currier
David Geffen School of Medicine, University of California los angeles
Co-authored papers 2
Douglas R Lowy
Co-authored papers 2
Dushyantha Jayaweera
University of Miami, Miller School of Medicine
Co-authored papers 2
Thomas G Stewart
Vanderbilt University Medical Center
Co-authored papers 2
Matthew W McCarthy
Weill Cornell Medical College, New York-Presbyterian Hospital
Co-authored papers 2
Joseph P Menetski
The Foundation for the National Institutes of Health
Co-authored papers 2
Roy S Herbst
Yale School of Medicine
Co-authored papers 2
Francis S Collins
University of Michigan ann arbor
Co-authored papers 2
Sarah E Dunsmore
National Center for Advancing Translational Sciences
Co-authored papers 2
Carolyn T Bramante
University of Minnesota
Co-authored papers 2
Adit A Ginde
University of Colorado School of Medicine
Co-authored papers 2
Pablo Tamayo
University of California San Diego
Co-authored papers 1
Rhonda Wilder
Duke Clinical Research Institute, Duke University School of Medicine
Co-authored papers 1
Mariano J Alvarez
Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center
Co-authored papers 1
Release 1.2